1,340 reports of this reaction
6.3% of all AXICABTAGENE CILOLEUCEL reports
#3 most reported adverse reaction
NEUROTOXICITY is the #3 most commonly reported adverse reaction for AXICABTAGENE CILOLEUCEL, manufactured by Kite Pharma, Inc.. There are 1,340 FDA adverse event reports linking AXICABTAGENE CILOLEUCEL to NEUROTOXICITY. This represents approximately 6.3% of all 21,373 adverse event reports for this drug.
Patients taking AXICABTAGENE CILOLEUCEL who experience neurotoxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROTOXICITY is moderately reported among AXICABTAGENE CILOLEUCEL users, representing a notable but not dominant share of adverse events.
In addition to neurotoxicity, the following adverse reactions have been reported for AXICABTAGENE CILOLEUCEL:
The following drugs have also been linked to neurotoxicity in FDA adverse event reports:
NEUROTOXICITY has been reported as an adverse event in 1,340 FDA reports for AXICABTAGENE CILOLEUCEL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROTOXICITY accounts for approximately 6.3% of all adverse event reports for AXICABTAGENE CILOLEUCEL, making it one of the most commonly reported side effect.
If you experience neurotoxicity while taking AXICABTAGENE CILOLEUCEL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.